Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 726

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Asthma

Not recruiting

Study on Tiotropium for Preventing Severe Asthma Attacks in Preschool Children with Uncontrolled Asthma

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tiotropium Bromide Monohydrate

Psoriasis

Not recruiting

Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab

Cholangiocarcinoma

Not recruiting

Study of Durvalumab with Gemcitabine and Cisplatin for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Renal cell carcinoma

Not recruiting

Study on the Safety and Effects of Volrustomig and Axitinib for Patients with Advanced Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study on the Safety of DNL310 for Children with Hunter Syndrome

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor

Breast cancer+3

Not recruiting

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.